	US 11,834,507 B2
	Anti-MET agonist antibody for use in the treatment of colorectal cancer
Paolo Michieli, Rivalta di Torino (IT)
Assigned to Agomab Therapeutics, Ghent (BE)
Appl. No. 16/959,713
Filed by AGOMAB THERAPEUTICS, Ghent (BE)
PCT Filed Jan. 3, 2019, PCT No. PCT/EP2019/050077 § 371(c)(1), (2) Date Jul. 2, 2020, PCT Pub. No. WO2019/134927, PCT Pub. Date Jul. 11, 2019.
Claims priority of application No. 102018000000535 (IT), filed on Jan. 3, 2018.
Prior Publication US 2021/0087281 A1, Mar. 25, 2021
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2863 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01)]

14 Claims

1. A method of treating colorectal cancer comprising administering to a subject suffering therefrom a MET agonist;

wherein the MET agonist is an anti-MET agonist antibody or antigen-binding fragment thereof comprising a VH CDR1 of sequence SEQ ID NO:30, a CDR2 of sequence SEQ ID NO:32, and a CDR3 of sequence SEQ ID NO:34, and a VL CDR1 of sequence SEQ ID NO:107, a CDR2 of sequence SEQ ID NO:109, and a CDR3 of sequence SEQ ID NO: 111, and

wherein the subject has been diagnosed with colorectal inflammation prior to administration of the MET agonist.